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 A new  ‘ tac ’ for childhood 
nephrotic syndrome 
 Brian  Becknell 1 ,  Larry A.  Greenbaum 2 and  William E.  Smoyer 1 , 3 
 Calcineurin inhibitors (CNIs) are frequent first-line agents in children 
with steroid-resistant nephrotic syndrome (SRNS). However, limited 
randomized controlled trial (RCT) data are available comparing CNIs 
with alternative therapies. Gulati and colleagues report their experience 
with tacrolimus versus cyclophosphamide in childhood SRNS. Their 
results establish clear superiority of tacrolimus over cyclophosphamide 
and give further proof that RCTs in childhood SRNS are both feasible 
and vital for improving the standard of care. 
 Kidney International (2012)  82, 1049 – 1051.  doi: 10.1038/ki.2012.272 
 Th e initial response to corticosteroids is the 
single best predictor of long-term prognosis 
in childhood nephrotic syndrome. Follow-
ing diagnosis of steroid-resistant nephrotic 
syndrome (SRNS), the risk of a histologic 
diagnosis of focal segmental glomerulo-
sclerosis (FSGS) and of the development of 
end-stage renal disease increases dramati-
cally, with FSGS causing more than 10 % of 
cases of end-stage renal disease in children. 1 
Pediatric nephrologists have prescribed a 
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variety of alternative therapies to improve 
this ominous outcome, but a paucity of 
randomized controlled trials (RCTs) has 
resulted in a lack of consensus regarding the 
optimal treatment of SRNS. 2 
 Calcineurin inhibitors (CNIs) are 
frequent first-line agents in children 
with SRNS. Cyclosporin A (CsA) is the 
oldest and best-studied CNI in nephrotic 
syndrome (NS). By complexing with cyclo-
philin, CsA inhibits the phosphatase 
activity of calcineurin and prevents T-cell 
activation. Tacrolimus (FK506) also acts via 
inhibition of calcineurin, but this occurs 
through its association with FK506-binding 
protein (FKBP) ( Figure 1 ). However, the 
mechanism of CNI action in NS is unclear. 
While the initial rationale for the use of 
CNIs in NS rested on their immunomodu-
latory properties, recent experimental 
evidence demonstrates that calcineurin is 
expressed by podocytes, and CNIs or podo-
cyte-specifi c inactivation of calcineurin 
stabilizes the podocyte actin cytoskeleton 
and reduces proteinuria in response to 
glomerular injury. 3 Unfortunately, pro-
longed use of CsA has been associated with 
interstitial fi brosis. Data are limited regard-
ing long-term outcomes and dose-related 
toxicity in children taking tacrolimus for 
NS. 4,5 In a retrospective single-center study, 
tacrolimus induced complete remission 
in 15 of 16 patients (94 % ) aft er a median 
of 120 days of therapy. 6 Higher trough 
levels and a duration of therapy longer than 
24 months were each associated with 
increased tubular atrophy and interstitial 
fibrosis, potentially attesting to risks of 
prolonged tacrolimus use similar to those 
encountered in patients on CsA. In addi-
tion, CsA and tacrolimus were recently 
compared in a single RCT, and found to 
be equally effi  cacious in childhood SRNS, 
with comparable nephrotoxic profi les. 5 
 Alkylating agents such as cyclophospha-
mide have also been used in NS, albeit 
more frequently in steroid-dependent 
or frequently relapsing NS than in SRNS. 
Th e mechanism of alkylating agents in NS 
is also unclear, but they are presumed 
to act via inhibition of immune cells. 
Dose-related toxicities of cyclophospha-
mide include bone marrow suppression, 
alopecia, hemorrhagic cystitis, severe 
bacterial infections, malignancies, and 
gonadal toxicity. Intravenous pulse cyclo-
phosphamide has been prescribed to 
patients with steroid-resistant FSGS and 
promoted remission in certain cases, parti-
cularly children with secondary steroid 
resistance. 7,8 A single RCT comparing 
alkylating agents and CNIs found that 
intravenous cyclophosphamide was infe-
rior to CsA in inducing a partial remission 
in pediatric SRNS. 9 
 Gulati and colleagues 10 (this issue) now 
present their fi ndings from the fi rst pro-
spective, randomized, multicenter trial of 
intravenous cyclophosphamide versus 
tacrolimus in 131 children with SRNS. 
Consecutive patients aged 2 – 16 years with 
biopsy-confi rmed minimal-change NS 
(MCNS), FSGS, or mesangioproliferative 
glomerulonephritis were stratifi ed by early 
and late steroid resistance and randomized 
to 12 months of tacrolimus or 6 monthly 
infusions of cyclophosphamide. Each 
group received alternate-day predni so-
lone. The primary end point was the 
proportion of patients with complete or 
commentar y
1050   Kidney International (2012) 82 
partial remission, on the basis of fi rst-
morning urine protein-to-creatinine 
ratios at 6 months. Complete or partial 
remission rates were higher in patients 
receiving tacrolimus (82.5 % ) versus cyclo-
phosphamide (45.9 % ), and sustained 
remission or steroid-sensitive disease 
was higher in the tacrolimus group at 12 
months (52.4 % versus 14.8 % ). In contrast, 
treatment withdrawal due to drug toxicity 
was higher among patients on cyclophos-
phamide (ten patients, eight because of 
serious infections) than tacrolimus (two 
withdrawals, both for nephrotoxicity). 
Notably, the most frequent adverse event 
with cyclophosphamide was serious infec-
tion (16 of 54 events), while the most 
common adverse event with tacrolimus 
was acute nephrotoxicity (9 of 45 events). 
Th e authors conclude that prescription of 
tacrolimus and prednisolone is eff ective, 
safe, and superior to intravenous cyclo-
phosphamide as the initial therapy for 
children with SRNS. 
 While the study authors attempted to dis-
tinguish between histopathologic variants 
of NS, a limitation of the current morpho-
logy-based classifi cation of NS is its reliance 
on the absence of a finding — segmental 
sclerosis — to distinguish MCNS from FSGS. 
Hence, sampling error can result in a missed 
diagnosis of FSGS. Although the con-
clusions of this study apply regardless of 
underlying histopathology, this diagnostic 
uncertainty is an important barrier to 
address in future studies of NS. 
 Multiple additional points raised by this 
study warrant further discussion. First, 
whereas FSGS accounts for 47.5 % of 
patients with SRNS, 11 the majority of 
patients enrolled by Gulati and colleagues 
had MCNS (59.5 % ), and FSGS accounted 
for only 32.8 % of cases. 10 While the study 
authors found that the likelihood of remis-
sion was higher with MCNS, it is note-
worthy that tacrolimus outperformed 
cyclophosphamide in promoting remis-
sion regardless of histopathology. Second, 
the authors acknowledge that their 
study was not stratifi ed by histopathologic 
diagnosis, and that inclusion of patients 
with MCNS may account for the higher 
remission rates in this study than in 
similar studies using CNIs in patients 
with FSGS. 12 Th ird, more than one-third 
(38.2 % ) of the cases treated by Gulati and 
colleagues had late (that is, secondary) 
steroid resistance, yet the superiority of 
tacrolimus over cyclophosphamide was 
maintained regardless of resistance type. 10 
Fourth, little genetic investigation was 
performed in these patients, although the 
role of genetic testing is unclear given the 
uncertain correlation between underlying 
DNA mutations and response to treat-
ment. Th us, it remains to be determined 
whether certain patient populations — 
defi ned genetically, morphologically, or 
otherwise — are less likely to respond to 
tacrolimus, or more likely to respond 
to an intervention such as intravenous 
cyclophosphamide. Finally, the impact of 
therapy beyond 12 months is not reported, 
so the potential nephrotoxicity of long-
term tacrolimus and the ability of pro-
longed tacrolimus to sustain remission 
beyond this time frame remain unad-
dressed in these patients. 
 The failure of treating nephrologists, 
in most cases to date, to enroll patients 
and base clinical decision making on the 
results of RCTs has impaired the ability to 
incorporate innovative, experimentally 
validated, and potentially superior treat-
ment approaches to improve outcomes in 
children with SRNS. Gulati and colleagues 
at the All India Institute of Medical Sciences 
should thus be congratulated for taking a 
new  ‘ tac ’ and performing a well-designed 
and -executed RCT that systematically 
compared two major alternative therapies 
to help clarify and improve the standard of 
care for pediatric SRNS. 10 With the superi-
ority of tacrolimus over cyclophosphamide 
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 Figure 1  |  Mechanism of Cyclosporin A (CsA) versus tacrolimus. CsA binds to cyclophilin (CpN) 
in the cytoplasm, and the CsA – CpN complex associates with and blocks calcineurin (CaN) activity. 
CaN is a serine-threonine phosphatase and, when inhibited, is unable to dephosphorylate the 
nuclear factor of activated T cells (NF-AT). Thus, NF-AT is retained in the cytoplasm and is unable 
to activate transcriptional targets such as interleukin-2, which is necessary for T-cell activation. 
Tacrolimus (FK506) associates with FK506-binding protein (FKBP), and the FK506 – FKBP complex 
binds to and blocks CaN activity. Thus, while CsA and FK506 bind to different proteins, their 
mechanism of T-cell inhibition is similar. 
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now clearly established, subsequent trials 
should directly compare other new thera-
peutic agents with tacrolimus, or system-
atically evaluate the addition of a second 
agent to maintain remission and abbreviate 
the duration of tacrolimus therapy. In addi-
tion, subsequent prospective trials of pedi-
atric SRNS should specifically stratify 
patients according to histopathology and 
potential biomarkers, 13 and also perform 
targeted genotyping for all currently recog-
nized genetic causes of SRNS. Such an 
approach will enable the development of a 
more personalized and eff ective therapeutic 
strategy for this vexing disease. 
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 A defect in vasopressin secretion 
in autosomal dominant 
polycystic kidney disease 
 Daniel G.  Bichet 1 
 A nephrogenic defect in urine concentration is well established in 
patients with polycystic kidney disease, but Ho  et al. report a defect in 
the increase of plasma vasopressin in response to dehydration. 
On a cellular level, transient receptor potential channels responsible for 
osmoperception could interact with TRPPs encoded by the polycystic 
genes  PKD1 and  PKD2 . 
 Kidney International (2012)  82, 1051 – 1053.  doi: 10.1038/ki.2012.271 
 Ho  et al. , 1 in this issue of  Kidney Interna-
tional , demonstrate that autosomal domi-
nant polycystic kidney disease (ADPKD) 
is associated not only with lower urinary 
osmolality but also with less vasopressin 
secretion. As PKD gene expression has 
been found in hypothalamic nuclei, these 
clinical observations suggest a specifi c role 
of PKD genes in osmoregulation. 
 A defect in renal concentrating 
capacity is well demonstrated in 
polycystic kidney disease 
 Martinez-Maldonado  et al. 2 published as 
early as 1972 that the inability to concentrate 
urine was a common fi nding both in chro-
nic kidney disease and in polycystic kidney 
disease (PKD). However, the urinary con-
centration defect was observed in ADPKD 
patients with normal renal function 3 and 
was probably related to physical alterations 
of the renal medulla by cysts originating in 
the collecting duct, principally the cortico-
medullary junction. In these early studies, 
an inverse correlation was demonstrated 
between urinary osmolality and renal 
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volume estimated by ultrasound. Measure-
ment of maximal urine osmolality aft er 
an overnight dehydration was then pro-
posed as an inexpensive way to screen for 
ADPKD as compared with the more costly 
renal ultrasound. 3 
 The new fi ndings of Ho  et al. : defective 
vasopressin release in patients with 
ADPKD 
 In the study by Ho  et al. , 1 adults and 
children with ADPKD were matched 
with unaff ected family members and 
demonstrated higher plasma osmolality 
and lower urinary osmolality (710 ver-
sus 920  mosmol / kg H 2 O) in response to 
dehy dration. Plasma vasopressin levels 
remained unchanged in adult ADPKD 
patients, contrasting with increased val-
ues in controls. Th ese vasopressin levels 
are critical, as patients with hereditary or 
acquired nephrogenic diabetes insipidus 
always have higher plasma vasopressin 
values. 4 
 Expression of  PKD1 and  PKD2 genes 
in the Allen Mouse and Human Brain 
Atlases 
 Th e Allen Institute for Brain Science, 
established in 2003 by Paul Allen (one of 
the original founders of Microsoft ), set out 
to describe the expression of all known 
genes in the adult mouse brain, 5,6 and 
colorimetric  in situ hybridization data for 
21,000 genes are now posted online with 
